POM-V Prescription Required

Emdofluxin 50 mg/mL Solution for Injection for Cattle, Horses and Pigs

Active ingredient: Flunixin

Form

Injection

Species

Cattle Horses Pigs

Manufacturer

Emdoka

VMD MA No.

34534/5007

What it's used for

Alleviation of acute inflammation and pain associated with musculoskeletal disorders. Reduction of post-operative pain associated with dehorning in calves...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Flunixin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Emdofluxin 50 mg/mL Solution for Injection for Cattle, Horses and Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Reduction of post-operative pain associated with dehorning in calves of less than 9
weeks.
Horses
Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Alleviation of visceral pain associated with colic.
Adjunctive therapy of endotoxemia due to or as a result of post-surgical or medical
conditions or diseases that result in impaired blood circulation in the gastrointestinal
tract.
Reduction of pyrexia.
Pigs
Adjunctive therapy in the treatment of swine respiratory disease.
Adjunctive treatment of postpartum dysgalactia (Mastitis-Metritis-Agalactia) syndrome
in sows.
Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Reduction of post-operative pain following castration and tail docking in sucking
piglets.

Intravenous use in horses.
Intramuscular use in pigs.
Cattle
Adjunctive therapy in the treatment of bovine respiratory diseases, endotoxemia and
acute mastitis and alleviation of acute inflammation and pain associated with
musculoskeletal disorders
2.2 mg flunixin/kg bodyweight (2 ml per 45 kg) once daily via intramuscular or
intravenous route. Repeat as necessary at 24-hour intervals for up to 3 consecutive
days.
The maximal volume to be administered per injection site is 20 mL.
Reduction of post-operative pain associated with dehorning in calves of less than 9
weeks
A single intravenous administration of 2.2 mg of flunixin per kg bodyweight (2 mL per
45 kg), 15-20 minutes before the procedure.
Horses
Alleviation of acute inflammation and pain associated with musculoskeletal disorders
and reduction of pyrexia
1.1 mg flunixin/kg bodyweight (1 ml per 45 kg) once daily for up to 5 days according
to clinical response.
Alleviation of visceral pain associated with colic
1.1 mg flunixin/kg bodyweight (1 ml per 45 kg). Repeat once or twice if colic recurs.
Adjunctive therapy of endotoxemia due to or as a result of post-surgical or medical
conditions or diseases that result in impaired blood circulation in the gastrointestinal
tract
0.25 mg flunixin/kg bodyweight every 6-8 hours or 1.1 mg flunixin/kg bodyweight
once daily for up to 5 consecutive days.
Pigs
Adjunctive therapy in the treatment of swine respiratory disease, adjunctive treatment
of postpartum dysgalactia (Mastitis-Metritis-Agalactia) syndrome in sows, alleviation
of acute inflammation and pain associated with musculoskeletal disorders
2.2 mg flunixin/kg bodyweight (2 ml per 45 kg) once daily for up to 3 consecutive
days. The injection volume should be limited to a maximum of 5 mL per injection site.
Reduction of post-operative pain following castration and tail docking in sucking
piglets
A single administration of 2.2 mg of flunixin per kg bodyweight (0.2 mL per 4.5 kg),
15-30 minutes before the procedure.
Particular care should be taken with regard to the accuracy of dosing including the
use of an appropriate dosing device and careful estimation of body weight.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
The vial should not be broached more than 25 times. Therefore the user should
select the most appropriate vial size according to the target species to be treated.
When treating several animals in one run, use a draw-off needle that has been
placed in the vial stopper to avoid excess broaching of the stopper. The draw-off
needle should be removed after treatment.

Do not use in animals suffering from cardiac, hepatic, or renal disease or where there
is the possibility of gastro-intestinal ulceration or bleeding.
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use if haematopoiesis or haemostasis is impaired.
Do not use in case of colic caused by ileus and associated with dehydration.

Cattle
Uncommon
(1 to 10 animals / 1,000
animals treated):
Injection site reaction (such as injection site irritation

and
injection site swelling).
Rare
(1 to 10 animals / 10,000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Anaphylaxis (e.g. Anaphylactic shock, Hyperventilation,
Convulsion, Collapse, Death)
Very rare
(<1 animal / 10,000
animals treated, including
isolated reports):
Ataxia
;
Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract haemorrhage, nausea,
blood in faeces, diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Appetite loss.
Particularly in hypovolaemic and hypotensive animals.
After intravenous administration. At the onset of the first symptoms, administration
should be stopped immediately and, if necessary, anti-shock treatment should be
started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins,
responsible for the initiation of parturition.
If the product is used in the period following parturition.
Horses
Uncommon
(1 to 10 animals / 1,000
animals treated):
Injection site reaction (such as injection site irritation

and
injection site swelling).
Rare
(1 to 10 animals / 10,000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Anaphylaxis (e.g. Anaphylactic shock, Hyperventilation,
Convulsion, Collapse, Death)
Very rare
(<1 animal / 10,000
animals treated, including
isolated reports):
Ataxia
;
Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract haemorrhage, nausea,
blood in faeces, diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Excitation
;
Muscle weakness
;
Appetite loss.
Particularly in hypovolaemic and hypotensive animals.
After intravenous administration. At the onset of the first symptoms, administration
should be stopped immediately and, if necessary, anti-shock treatment should be
started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins,
responsible for the initiation of parturition.
If the product is used in the period following parturition.
May occur through accidental intra-arterial injection.
Pigs
Uncommon
(1 to 10 animals / 1,000
animals treated):
Injection site reaction (such as injection site skin discolouration,
injection site pain, injection site irritation

and injection site
swelling)
.
Rare
(1 to 10 animals / 10,000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Very rare
(<1 animal / 10,000
animals treated, including
isolated reports):
Anaphylaxis (e.g. Anaphylactic shock, Hyperventilation,
Convulsion, Collapse, Death)
;
Ataxia
;
Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract haemorrhage,
vomiting, nausea, blood in faeces, diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Appetite loss.
Resolves spontaneously within 14 days.
Particularly in hypovolaemic and hypotensive animals.
After intravenous
administration. At the onset of the first symptoms, administration should be stopped
immediately and, if necessary, anti-shock treatment should be started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins,
responsible for the initiation of parturition.
If the product is used in the period following parturition.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
Inject slowly as life threating symptoms of shock can occur due to the content of
propylene glycol.
NSAIDs are known to have the potential to delay parturition through a tocolytic effect
by inhibiting prostaglandins that are important in signaling the initiation of parturition.
The use of the veterinary medicinal product in the immediate post-partum period may
interfere with uterine involution and expulsion of foetal membrances resulting in
retained placentae.
The veterinary medicinal product should have a temperature close to body
temperature. Stop injection immediately after first symptoms of shock and start shock
treatment if necessary.
Use of NSAIDs in hypovolemic animals or animals with shock should be subject to a
benefit-risk evaluation performed by the responsible veterinarian due to the risk of
renal toxicity.
Use in very young (cattle, horses: less than 6 weeks old) as well as in old animals
may involve additional risks. If such treatment cannot be avoided, careful clinical
observation is indicated. The underlying cause of pain, inflammation or colic should
be determined and, when appropriate, antibiotic or re-hydration therapy should be
given concurrently.
NSAIDs can cause phagocytosis inhibition and, therefore, in the treatment of
inflammatory states associated with bacterial infections, appropriate concurrent
antimicrobial therapy should be established.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This veterinary medicinal product may cause hypersensitivity (allergy) reactions.
People with known hypersensitivity to non-steroidal anti-inflammatory drugs such as
flunixin and/or to propylene glycol should avoid contact with the veterinary medicinal
product. In case of hypersensitivity reactions seek medical advice and show the
package leaflet or the label to the physician.
This veterinary medicinal product may cause skin and eye irritation. Avoid contact
with skin or eyes. Wash hands after use. In case of accidental skin contact, wash
affected area immediately with plenty of water.
In case of accidental eye contact, rinse eyes immediately with plenty of water. If skin
and /or eye irritation persists, seek medical advice immediately and show the
package leaflet or the label to the physician.
Accidental self-injection may cause pain and inflammation. In case of accidental self-
injection, seek medical advice immediately and show the package leaflet or the label
to the physician.
Laboratory studies in rats with flunixin have shown evidence of foetotoxic effects.
Pregnant women should use the veterinary medicinal product with serious caution to
avoid accidental self-injection.
Special precautions for the protection of the environment:
Flunixin is toxic to avian scavengers. Do not administer to animals susceptible to
enter wild fauna food chain. In case of death or sacrifice of treated animals, ensure
that they are not made available to wild fauna.

Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently
or within 24 hours of each other. Do not administer corticosteroids concurrently.
Concurrent use of other NSAIDs or corticosteroids may increase the risk of gastro-
intestinal ulceration.
Some NSAIDs may be highly bound to plasma proteins and compete with other
highly bound drugs which can lead to toxic effects.
Flunixin may decrease the effect of some antihypertensive drugs by inhibiting
prostaglandin synthesis, such as diuretics, ACE inhibitors (angiotensin converting
enzyme inhibitors) and
Concomitant administration of potentially nephrotoxic drugs (e.g., aminoglycoside
antibiotics) should be avoided.

Keep the vial in the outer carton in order to protect from light.

Cattle:
Meat and offal: 4 days (intravenous use).
31 days (intramuscular use).
Milk: 24 hours (intravenous use).
36 hours (intramuscular use).
Horses:
Meat and offal: 5 days (intravenous use).
Not authorised for use in animals producing milk for human consumption.
Pigs
Meat and offal: 24 days (intramuscular use).

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.